Live Breaking News & Updates on Domain Niemann Pick

Stay updated with breaking news from Domain niemann pick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo

Cyclo Therapeutics (CYTH) Reports Publication of Data from Phase 2 Study of Trappsol Cyclo
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Caroline Hastings , Jenene Thomas , Company Trappsol , Company Phase , Global Principal Investigator For The Company , Program Steering Committee , Cyclo Therapeutics Inc , Exchange Commission , Cyclo Therapeutics , Molecular Genetics , Global Principal Investigator , Scott Fine , Chief Executive Officer , Domain Niemann Pick , Clinical Severity Scale , Orphan Drug Designation , Fast Track , Rare Pediatric Disease Designations , Rare Pediatric Disease Designation , Priority Review Voucher , Expanded Access ,

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

– Data published in official journal of Molecular Genetics and Metabolism Reports:

Evidence of a change in cholesterol homeostasis in peripheral organs and the brain after the initial infusion

Trappsol® Cyclo™ was detected in the CSF

Completers had an 88.9% improvement in at least two domains of the 17-Domain Niemann-Pick Type C1 Clinical Severity Scale (17D-NPC-CSS)

Improvement in Scale Assessment and Rating of Ataxia (SARA) score for the mean score in 7 of 8 domains at Week 48 compared with baseline

Demonstrated a favorable benefit-risk profile ....

United States , Caroline Hastings , Company Phase , Global Principal Investigator For The Company , Program Steering Committee , Exchange Commission , Cyclo Therapeutics Inc , Company Trappsol , Cyclo Therapeutics , Molecular Genetics , Global Principal Investigator , Chief Executive Officer , Domain Niemann Pick , Clinical Severity Scale , Orphan Drug Designation , Fast Track , Rare Pediatric Disease Designations , Rare Pediatric Disease Designation , Priority Review Voucher , Expanded Access ,